A perfect storm for biotech stocks
World of DTC Marketing
FEBRUARY 1, 2022
It dropped more than 15% in 2016 and followed that up with a 44% rise in 2017. Meanwhile, the Food and Drug Administration has delayed several drug approvals, and Sen. introduced sweeping drug-pricing legislation. 1ne: More scrutinization by the FDA on new drug applications. Bernie Sanders, I-Vt.,
Let's personalize your content